Trial Profile
Multicenter phase I/II study of switching therapy from lenalidomide and dexamethasone to elotuzumab plus lenalidomide and dexamethasone for multiple myeloma patients not achieving deep response
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Jun 2018
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms EAO-18
- 11 Jun 2018 New trial record